- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Evommune, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.04. | Oppenheimer initiates Evommune stock rating at Outperform, $50 target | 4 | Investing.com | ||
| 07.04. | Evommune: Oppenheimer startet Coverage mit "Outperform" und sieht über 100 % Kurspotenzial | 4 | Investing.com Deutsch | ||
| 18.03. | H.C. Wainwright cuts Evommune stock price target on dilution | 8 | Investing.com | ||
| 18.03. | This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday | 1 | Benzinga.com | ||
| 17.03. | Clear Street initiates Evommune stock with buy rating on drug potential | 4 | Investing.com | ||
| EVOMMUNE Aktie jetzt für 0€ handeln | |||||
| 12.03. | Leerink reiterates Evommune stock rating after conference chat | 1 | Investing.com | ||
| 11.03. | Evommune: RBC Capital startet Coverage mit "Outperform" und sieht 100 % Kurspotenzial | 1 | Investing.com Deutsch | ||
| 11.03. | RBC Capital initiates Evommune stock with outperform rating | 1 | Investing.com | ||
| 06.03. | Evommune, Inc Loss At -$28.27 Mln In Q4 | - | RTTNews | ||
| 06.03. | Evommune, Inc. GAAP EPS of -$11.22, revenue of $13M | 1 | Seeking Alpha | ||
| 05.03. | Evommune, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 05.03. | Evommune, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 05.03. | Evommune, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.02. | Evommune beschafft 125 Millionen US-Dollar über Privatplatzierung für Forschung und Entwicklung | 3 | Investing.com Deutsch | ||
| 13.02. | Evommune raises $125 million in private placement to fund R&D | 1 | Investing.com | ||
| 13.02. | Evommune raises $125M privately | 1 | Seeking Alpha | ||
| 12.02. | Evommune Stock Cools Off After Big Rally On Successful Eczema Trial | 2 | Benzinga.com | ||
| 11.02. | Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill | 7 | BioPharma Dive | ||
| 10.02. | Evommune Starts Making Case to Challenge Dominance of Sanofi's Dupixent in Atopic Dermatitis | 27 | MedCity News |
1 2 3 4 Weiter >>
61 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ATAIBECKLEY | 3,280 | +0,61 % | Analysten schwärmen nur so: Ataibeckley: Nur Kaufempfehlungen - Potenzial von 200 bis 500 Prozent! | © Foto: DALL-E Jeder Anleger ist auf der Suche nach der Aktie, die im Depot explodiert. Für eine solche Entwicklung müssen Investoren früh an Bord gehen. Ataibeckley könnte so ein Papier sein, dass... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 3,130 | +0,97 % | Aktien New York: Weitere Verluste - Iran-Krieg und China-News belasten | NEW YORK (dpa-AFX) - Die US-Aktienmärkte haben am Freitag ihre Talfahrt fortgesetzt. Der anhaltende Iran-Krieg und die weiter steigenden Ölpreise mahnen die Anleger zur Vorsicht. Auf die Stimmung drückte... ► Artikel lesen | |
| CORCEPT THERAPEUTICS | 36,690 | -0,92 % | Bronstein, Gewirtz & Grossman, LLC: Bronstein, Gewirtz & Grossman LLC Urges Corcept Therapeutics Incorporated Investors to Act: Class Action Filed Alleging Investor Harm | New York, New York--(Newsfile Corp. - April 14, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed... ► Artikel lesen | |
| KURA ONCOLOGY | 7,780 | +0,26 % | Kura Oncology, Inc.: Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026 | ||
| CELCUITY | 102,00 | -0,97 % | Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | The U.S. Food and Drug Administration ("FDA") accepted Celcuity's New Drug Application ("NDA") and granted Priority Review with a Prescription Drug User Fee Act ("PDUFA") goal date of July 17, 2026... ► Artikel lesen | |
| IMMUNOVANT | 26,550 | +5,65 % | Immunovant Inc.: Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) | Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 20,850 | +4,17 % | Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst | ||
| NURIX THERAPEUTICS | 16,300 | +2,45 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update | Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Enabling Phase 3 DAYBreak CLL-306 bexobrutideg... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 14,350 | +0,70 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones | Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expansion cohorts to determine recommended... ► Artikel lesen | |
| TREVI THERAPEUTICS | 14,040 | +5,25 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates | Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough On track... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 9,660 | -3,88 % | 4D Molecular Therapeutics, Inc.: 4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones | Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initial projections and reflecting strong interest from investigators and patients; topline data... ► Artikel lesen | |
| ERASCA | 17,830 | +9,32 % | Jefferies reiterates Erasca stock Buy rating on rival trial data | ||
| ZENAS BIOPHARMA | 21,340 | +1,33 % | Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) | - Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD flare - - Obexelimab also met and demonstrated statistically... ► Artikel lesen | |
| TYRA BIOSCIENCES | 35,240 | -1,04 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| TANGO THERAPEUTICS | 24,070 | +11,75 % | Leerink raises Tango Therapeutics stock price target on PDAC data |
Das Unternehmen EVOMMUNE INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 26,560 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EVOMMUNE INC finden Sie auf Wallstreet Online.